DelveInsight's "Non-Alcoholic Fatty Liver Disease (NAFLD) Market Insights, Epidemiology, and Market Forecast 2032" report delivers an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the Non-Alcoholic Fatty Liver Disease (NAFLD) Market size, share, and trends in the seven major market (7MM) (i.e., the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan).
The Non-Alcoholic Fatty Liver Disease (NAFLD) market report covers emerging drugs, current treatment practices, market share of the individual therapies, and current & forecasted market size from 2019 to 2032. It also evaluates the current treatment practice/algorithm, market drivers & barriers, and unmet medical needs to curate the best of the opportunities and assess the underlying potential of the market.
Non-Alcoholic Fatty Liver Disease: An Overview
Non-alcoholic Fatty Liver Disease (NAFLD) is a very common disorder and refers to a group of conditions where there is an accumulation of excess fat in the liver of people who drink little or no alcohol. The most common form of NAFLD is a nonserious condition called fatty liver. In fatty liver, fat accumulates in the liver cells.
Although having fat in the liver is not normal by itself, it probably does not damage the liver. A small group of people with NAFLD may have a more serious condition named non-alcoholic steatohepatitis (NASH). In NASH, fat accumulation is associated with liver cell inflammation and different degrees of scarring. NASH is a potentially serious condition that may lead to severe liver scarring and cirrhosis.
Non-Alcoholic Fatty Liver Disease Market Key Facts
-
According to American Liver Foundation (n.d.), NAFLD is the most common chronic liver condition in the United States. It’s estimated that about 25% of adults in the U.S. have NAFLD. Of those with NAFLD, about 20% have NASH (5% of adults in the US). Most people with NAFLD have simply fatty liver.
-
As per the study conducted by Soresi et al. (2013), titled “Nonalcoholic fatty liver and metabolic syndrome in Italy: results from a multicentric study of the Italian Arteriosclerosis society,” NAFLD was detected in 160 out of 203 metabolic syndrome (MS) patients, with a prevalence of 78.8%.
Non-Alcoholic Fatty Liver Disease Market
The market outlook section of the report helps to build a detailed comprehension of the historical, current, and forecasted Non-Alcoholic Fatty Liver Disease market size by analyzing the impact of current and emerging therapies in the market. It also provides a thorough assessment of the market drivers & barriers, unmet needs, and emerging technologies.
The report details the Non-Alcoholic Fatty Liver Disease market trend for each marketed drug and late-stage pipeline therapy by evaluating their impact based on the annual cost of therapy, mechanism of action (MoA), competition with other therapies, brand value, and their impact on the market.
Non-Alcoholic Fatty Liver Disease Epidemiology
The epidemiology section provides insights into the historical, current, and forecasted epidemiology trends in the seven major countries (7MM) from 2019 to 2032. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. The epidemiology section also provides a detailed analysis of diagnosed patient pool and future trends.
Non-Alcoholic Fatty Liver Disease (NAFLD) Epidemiology Segmentation
-
Total Prevalent Cases of Non-alcoholic Fatty Liver Disease (NAFLD)
-
Type-specific Prevalent Cases of Non-alcoholic Fatty Liver Disease (NAFLD)
-
Diagnosed and Treatable Cases of Non-alcoholic Fatty Liver Disease (NAFLD)
Non-Alcoholic Fatty Liver Disease Drugs Uptake and Pipeline Development Activities
The drugs uptake section focuses on the rate of uptake of the potential drugs recently launched in the Non-Alcoholic Fatty Liver Disease market or expected to get launched during the study period. The analysis covers Non-Alcoholic Fatty Liver Disease market uptake by drugs, patient uptake by therapies, and sales of each drug.
Moreover, the therapeutics assessment section helps understand the drugs with the most rapid uptake and the reasons behind the maximal use of the drugs. Additionally, it compares the drugs based on market share.
The report also covers the Non-Alcoholic Fatty Liver Disease Pipeline Development Activities. It provides valuable insights about different therapeutic candidates in various stages and the key companies involved in developing targeted therapeutics. It also analyses recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.
Request for Sample PDF Report - https://www.delveinsight.com/sample-request/non-alcoholic-fatty-liver-disease-nafld-market
Non-Alcoholic Fatty Liver Disease Therapeutics Analysis
Globally, sever key players are actively working to develop potential therapies for the treatment of Non-alcoholic Fatty Liver Disease (NAFLD). The launch of the therapies is expected to transform the treatment dynamics.
Some of the key companies in the Non-Alcoholic Fatty Liver Disease (NAFLD) Market include:
-
Madrigal Pharmaceuticals, Inc.
-
Cirius Therapeutics
-
Novo Nordisk A/S
-
Intercept Pharmaceuticals
And others
Non-Alcoholic Fatty Liver Disease (NAFLD) Therapies covered in the report include:
-
Resmetirom (MGL-3196)
-
MSDC- 0602K
-
Semaglutide
-
Ocalive (obeticholic acid or OCA)
And many more
The pipeline for Non-alcoholic Fatty Liver Disease (NAFLD) brings a positive ray of hope for a better treatment pattern in the market in the upcoming years.
Get More Detailed Insights Into the Emerging Therapies & Key Companies -
https://www.delveinsight.com/sample-request/non-alcoholic-fatty-liver-disease-nafld-market
Table of Content (TOC)
1. Key Insights
2. Executive Summary
3. Non-Alcoholic Fatty Liver Disease Competitive Intelligence Analysis
4. Non-Alcoholic Fatty Liver Disease Market Overview at a Glance
5. Non-Alcoholic Fatty Liver Disease Disease Background and Overview
6. Non-Alcoholic Fatty Liver Disease Patient Journey
7. Non-Alcoholic Fatty Liver Disease Epidemiology and Patient Population
8. Non-Alcoholic Fatty Liver Disease Treatment Algorithm, Current Treatment, and Medical Practices
9. Non-Alcoholic Fatty Liver Disease Unmet Needs
10. Key Endpoints of Non-Alcoholic Fatty Liver Disease Treatment
11. Non-Alcoholic Fatty Liver Disease Marketed Products
12. Non-Alcoholic Fatty Liver Disease Emerging Therapies
13. Non-Alcoholic Fatty Liver Disease Seven Major Market Analysis
14. Attribute Analysis
15. Non-Alcoholic Fatty Liver Disease Market Outlook (7 major markets)
16. Non-Alcoholic Fatty Liver Disease Access and Reimbursement Overview
17. KOL Views on the Non-Alcoholic Fatty Liver Disease Market.
18. Non-Alcoholic Fatty Liver Disease Market Drivers
19. Non-Alcoholic Fatty Liver Disease Market Barriers
20. Appendix
21. DelveInsight Capabilities
22. Disclaimer
*The Table of Contents (TOC) is not exhaustive; the final content may vary. Refer to the sample report for the complete table of contents.
Download Sample PDF Report - https://www.delveinsight.com/sample-request/non-alcoholic-fatty-liver-disease-nafld-market
About DelveInsight
DelveInsight is a leading Business Consultant and Market Research Firm focused exclusively on life sciences. It supports pharma companies by providing comprehensive end-to-end solutions to improve their performance.
Other Trending Healthcare Reports by DelveInsight
Juvenile Idiopathic Arthritis (JIA) Market
“Juvenile Idiopathic Arthritis (JIA) Market” research report provides a detailed overview of the historical and forecasted epidemiology as well as the Juvenile Idiopathic Arthritis (JIA) Market size, share, and trends in the 7MM (i.e. the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan). Additionally, it also covers the latest innovations, breakthroughs, emerging therapies, and key companies operating in the therapeutics market.
Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Shruti Thakur
Email:Send Email
Phone: 9193216187
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: Nevada
Country: United States
Website: https://www.delveinsight.com/
